Cargando…
A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma
Copper-induced death, also termed cuproptosis, is a novel form of programmed cell death and is promising as a new strategy for cancer therapeutics. Elevated copper levels in tumor cells are positively associated with high PD-L1 expression. Nonetheless, the prognostic significance of cuproptosis-rela...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630496/ https://www.ncbi.nlm.nih.gov/pubmed/36323801 http://dx.doi.org/10.1038/s41598-022-22962-y |
_version_ | 1784823615226642432 |
---|---|
author | Xie, Yusai Zhang, Wei Sun, Jia Sun, Lingyan Meng, Fanjie Yu, Huiying |
author_facet | Xie, Yusai Zhang, Wei Sun, Jia Sun, Lingyan Meng, Fanjie Yu, Huiying |
author_sort | Xie, Yusai |
collection | PubMed |
description | Copper-induced death, also termed cuproptosis, is a novel form of programmed cell death and is promising as a new strategy for cancer therapeutics. Elevated copper levels in tumor cells are positively associated with high PD-L1 expression. Nonetheless, the prognostic significance of cuproptosis-related immune checkpoint genes (CRICGs) in hepatocellular carcinoma remains to be further clarified. This study aimed to construct the prognostic CRICG signature to predict the immunotherapy response and outcomes of HCC patients. The co-expressed CRICGs were first screened through Pearson correlation analysis. Based on the least absolute shrinkage and selection operator-COX regression analyses, we identified a prognostic 5-CRICGs model, which closely correlates with poor outcomes, cancer development, and immune response to hepatocellular carcinoma. External validation was conducted using the GSE14520 dataset. Lastly, qRT-PCR was performed to determine the expression of the CRICGs in HCC. In summary, we developed and validated a novel prognostic CRICG model based on 5 CRICGs. This prognostic signature could effectively forecast the outcomes and immune response of HCC patients, which may serve as biomarkers for anticancer therapy. |
format | Online Article Text |
id | pubmed-9630496 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96304962022-11-04 A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma Xie, Yusai Zhang, Wei Sun, Jia Sun, Lingyan Meng, Fanjie Yu, Huiying Sci Rep Article Copper-induced death, also termed cuproptosis, is a novel form of programmed cell death and is promising as a new strategy for cancer therapeutics. Elevated copper levels in tumor cells are positively associated with high PD-L1 expression. Nonetheless, the prognostic significance of cuproptosis-related immune checkpoint genes (CRICGs) in hepatocellular carcinoma remains to be further clarified. This study aimed to construct the prognostic CRICG signature to predict the immunotherapy response and outcomes of HCC patients. The co-expressed CRICGs were first screened through Pearson correlation analysis. Based on the least absolute shrinkage and selection operator-COX regression analyses, we identified a prognostic 5-CRICGs model, which closely correlates with poor outcomes, cancer development, and immune response to hepatocellular carcinoma. External validation was conducted using the GSE14520 dataset. Lastly, qRT-PCR was performed to determine the expression of the CRICGs in HCC. In summary, we developed and validated a novel prognostic CRICG model based on 5 CRICGs. This prognostic signature could effectively forecast the outcomes and immune response of HCC patients, which may serve as biomarkers for anticancer therapy. Nature Publishing Group UK 2022-11-02 /pmc/articles/PMC9630496/ /pubmed/36323801 http://dx.doi.org/10.1038/s41598-022-22962-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Xie, Yusai Zhang, Wei Sun, Jia Sun, Lingyan Meng, Fanjie Yu, Huiying A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma |
title | A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma |
title_full | A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma |
title_fullStr | A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma |
title_full_unstemmed | A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma |
title_short | A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma |
title_sort | novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630496/ https://www.ncbi.nlm.nih.gov/pubmed/36323801 http://dx.doi.org/10.1038/s41598-022-22962-y |
work_keys_str_mv | AT xieyusai anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT zhangwei anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT sunjia anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT sunlingyan anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT mengfanjie anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT yuhuiying anovelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT xieyusai novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT zhangwei novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT sunjia novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT sunlingyan novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT mengfanjie novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma AT yuhuiying novelcuproptosisrelatedimmunecheckpointgenesignatureidentificationandexperimentalvalidationinhepatocellularcarcinoma |